Cargando…

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection

BACKGROUND: ME1100 (arbekacin inhalational solution) is an inhaled aminoglycoside being developed to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). PK-PD target attainment analyses were undertaken to evaluate ME1100 regimens for pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhavnani, Sujata M, Hammel, Jeffrey P, Lakota, Elizabeth A, VanScoy, Brian D, Nagira, Yu, Rubino, Christopher M, Sato, Nobuo, Koresawa, Tomokazu, Kondo, Kenichiro, Ambrose, Paul G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252562/ http://dx.doi.org/10.1093/ofid/ofy210.1223

Ejemplares similares

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae
por: Bhavnani, Sujata M., et al.
Publicado: (2023)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

1379. Determination of the Arbekacin Exposure Required to Prevent Amplification of Resistant Subpopulations Using Patient Pharmacokinetics Simulated in a Hollow-Fiber Infection Model (HFIM)
por: VanScoy, Brian D, et al.
Publicado: (2018)

Pharmacokinetic-Pharmacodynamic Characterization of Omadacycline against Haemophilus influenzae Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes
por: Bulik, Catharine C, et al.
Publicado: (2017)

1565. Characterization of Tebipenem (SPR859) Pharmacokinetics–Pharmacodynamics (PK-PD) for Efficacy Against Enterobacteriaceae in a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2019)

Gepotidacin Pharmacokinetics-Pharmacodynamics against Escherichia coli in the One-Compartment and Hollow-Fiber In Vitro Infection Model Systems
por: VanScoy, Brian D., et al.
Publicado: (2021)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints
por: Bhavnani, S. M., et al.
Publicado: (2022)

2552. Comparative Pharmacodynamic Evaluation of Commonly Utilized, Oral, 1(st) - 3(rd) Generation Cephalosporins against S. aureus and E. coli in the Mouse Thigh Infection Model
por: Lepak, Alexander, et al.
Publicado: (2023)

Traditional PK-PD Indices for Efficacy – Can We Do Better?
por: Lakota, Elizabeth A, et al.
Publicado: (2017)

733. Pharmacokinetic–Pharmacodynamic (PK–PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

2562. Re-Appraisal of Aminoglycoside (AG) Susceptibility Testing Breakpoints Based on the Application of Pharmacokinetics–Pharmacodynamics (PK-PD) and Contemporary Microbiology Surveillance Data
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia
por: Bader, Justin C, et al.
Publicado: (2017)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
por: Lepak, Alexander J, et al.
Publicado: (2017)

Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow-Fiber In Vitro Infection Model
por: VanScoy, B. D., et al.
Publicado: (2023)

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

1095. Pharmacokinetics-Pharmacodynamics Evaluation of Tebipenem Pivoxil Hydrobromide Using the 10-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2021)

Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D., et al.
Publicado: (2020)

Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis
por: Rubino, Christopher M, et al.
Publicado: (2017)

Time for Precision: A World Without Susceptibility Breakpoints
por: Bader, Justin C, et al.
Publicado: (2018)

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data
por: Trang, Michael, et al.
Publicado: (2018)

Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
por: Zhang, Longfei, et al.
Publicado: (2022)

Pharmacodynamic Target Attainment for Meropenem and Piperacillin/Tazobactam Using a PK/PD-based Dosing Calculator in Critically Ill Patients
por: Heil, Emily, et al.
Publicado: (2017)

976. Population Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analysis of Intravenous Fosfomycin for Treatment of Multidrug-Resistant Gram-Negative Bacterial Infections
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

1392. Tuberculosis Disease in Recipients of Organ-Transplantation, California 2010–2017
por: Katrak, Shereen, et al.
Publicado: (2019)

1392. Nontuberculous Mycobacteria Isolated from Wisconsin Residents, 2010-2018
por: Vonasek, Bryan J, et al.
Publicado: (2021)

History of the medical licensing examination (uieop) in Korea’s Goryeo Dynasty (918-1392)
por: Lee, Kyung-Lock
Publicado: (2015)

Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients
por: Liang, J., et al.
Publicado: (2017)

1113. Oral Tebipenem as Step-Down Therapy Following Intravenous Ertapenem in a 7-day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2021)

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters
por: Lakota, Elizabeth A., et al.
Publicado: (2017)

1392. An observational study to test efficacy of oral fluconazole in pediatric cases of Cutaneous Leishmaniasis
por: Mitra, Debdeep
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u0rli2tonvndbn0im05el4a242